FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:FBL-RYR1 (FusionGDB2 ID:29440)

Fusion Gene Summary for FBL-RYR1

check button Fusion gene summary
Fusion gene informationFusion gene name: FBL-RYR1
Fusion gene ID: 29440
HgeneTgene
Gene symbol

FBL

RYR1

Gene ID

2091

6261

Gene namefibrillarinryanodine receptor 1
SynonymsFIB|FLRN|Nop1|RNU3IP1CCO|MHS|MHS1|PPP1R137|RYDR|RYR|RYR-1|SKRR
Cytomap

19q13.2

19q13.2

Type of geneprotein-codingprotein-coding
DescriptionrRNA 2'-O-methyltransferase fibrillarin34 kDa nucleolar scleroderma antigen34-kD nucleolar scleroderma antigenRNA, U3 small nucleolar interacting protein 1histone-glutamine methyltransferaseryanodine receptor 1central core disease of muscleprotein phosphatase 1, regulatory subunit 137ryanodine receptor 1 (skeletal)sarcoplasmic reticulum calcium release channelskeletal muscle calcium release channelskeletal muscle ryanodine receptortyp
Modification date2020031320200328
UniProtAcc

P22087

.
Ensembl transtripts involved in fusion geneENST00000221801, ENST00000593503, 
ENST00000355481, ENST00000360985, 
ENST00000359596, 
Fusion gene scores* DoF score11 X 9 X 4=39611 X 9 X 5=495
# samples 1111
** MAII scorelog2(11/396*10)=-1.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(11/495*10)=-2.16992500144231
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: FBL [Title/Abstract] AND RYR1 [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointFBL(40336931)-RYR1(39055599), # samples:2
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneFBL

GO:0031167

rRNA methylation

30540930

HgeneFBL

GO:1990258

histone glutamine methylation

24352239|30540930

TgeneRYR1

GO:0001666

response to hypoxia

19120137


check buttonFusion gene breakpoints across FBL (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check buttonFusion gene breakpoints across RYR1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4SKCMTCGA-ER-A19T-01AFBLchr19

40336931

-RYR1chr19

39055599

+
ChimerDB4SKCMTCGA-ER-A19T-01AFBLchr19

40336931

-RYR1chr19

39055599

+


Top

Fusion Gene ORF analysis for FBL-RYR1

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
In-frameENST00000221801ENST00000355481FBLchr19

40336931

-RYR1chr19

39055599

+
In-frameENST00000221801ENST00000360985FBLchr19

40336931

-RYR1chr19

39055599

+
In-frameENST00000221801ENST00000359596FBLchr19

40336931

-RYR1chr19

39055599

+
intron-3CDSENST00000593503ENST00000355481FBLchr19

40336931

-RYR1chr19

39055599

+
intron-3CDSENST00000593503ENST00000360985FBLchr19

40336931

-RYR1chr19

39055599

+
intron-3CDSENST00000593503ENST00000359596FBLchr19

40336931

-RYR1chr19

39055599

+

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000221801FBLchr1940336931-ENST00000355481RYR1chr1939055599+27611241872616809
ENST00000221801FBLchr1940336931-ENST00000360985RYR1chr1939055599+27611241872616809
ENST00000221801FBLchr1940336931-ENST00000359596RYR1chr1939055599+26171241872616810

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000221801ENST00000355481FBLchr1940336931-RYR1chr1939055599+0.0021406760.9978593
ENST00000221801ENST00000360985FBLchr1940336931-RYR1chr1939055599+0.0021406760.9978593
ENST00000221801ENST00000359596FBLchr1940336931-RYR1chr1939055599+0.0022639940.997736

Top

Fusion Genomic Features for FBL-RYR1


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)
FBLchr1940336930-RYR1chr1939055598+7.40E-101
FBLchr1940336930-RYR1chr1939055598+7.40E-101

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for FBL-RYR1


check button Go to

FGviewer for the breakpoints of chr19:40336931-chr19:39055599

.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
FBL

P22087

.
FUNCTION: S-adenosyl-L-methionine-dependent methyltransferase that has the ability to methylate both RNAs and proteins (PubMed:24352239, PubMed:30540930, PubMed:32017898). Involved in pre-rRNA processing by catalyzing the site-specific 2'-hydroxyl methylation of ribose moieties in pre-ribosomal RNA (PubMed:30540930). Site specificity is provided by a guide RNA that base pairs with the substrate (By similarity). Methylation occurs at a characteristic distance from the sequence involved in base pairing with the guide RNA (By similarity). Probably catalyzes 2'-O-methylation of U6 snRNAs in box C/D RNP complexes (PubMed:32017898). U6 snRNA 2'-O-methylation is required for mRNA splicing fidelity (PubMed:32017898). Also acts as a protein methyltransferase by mediating methylation of 'Gln-105' of histone H2A (H2AQ104me), a modification that impairs binding of the FACT complex and is specifically present at 35S ribosomal DNA locus (PubMed:24352239, PubMed:30540930). {ECO:0000250|UniProtKB:P15646, ECO:0000269|PubMed:24352239, ECO:0000269|PubMed:30540930, ECO:0000269|PubMed:32017898}.FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054462_45324203.05034.0Compositional biasNote=Pro-rich
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064462_45324208.05039.0Compositional biasNote=Pro-rich
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054462_45324203.05034.0Compositional biasNote=Pro-rich
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054881_49004203.05034.0IntramembranePore-forming
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064881_49004208.05039.0IntramembranePore-forming
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054881_49004203.05034.0IntramembranePore-forming
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054895_49014203.05034.0MotifSelectivity filter
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064895_49014208.05039.0MotifSelectivity filter
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054895_49014203.05034.0MotifSelectivity filter
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054210_42144203.05034.0Nucleotide bindingATP
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054955_49604203.05034.0Nucleotide bindingATP
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054980_49864203.05034.0Nucleotide bindingATP
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064210_42144208.05039.0Nucleotide bindingATP
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064955_49604208.05039.0Nucleotide bindingATP
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064980_49864208.05039.0Nucleotide bindingATP
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054210_42144203.05034.0Nucleotide bindingATP
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054955_49604203.05034.0Nucleotide bindingATP
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054980_49864203.05034.0Nucleotide bindingATP
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054581_46414203.05034.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054663_47804203.05034.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054804_48044203.05034.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054822_48364203.05034.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054858_48804203.05034.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054901_49204203.05034.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054942_50384203.05034.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064581_46414208.05039.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064663_47804208.05039.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064804_48044208.05039.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064822_48364208.05039.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064858_48804208.05039.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064901_49204208.05039.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064942_50384208.05039.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054581_46414203.05034.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054663_47804203.05034.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054804_48044203.05034.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054822_48364203.05034.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054858_48804203.05034.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054901_49204203.05034.0Topological domainLumenal
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054942_50384203.05034.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054560_45804203.05034.0TransmembraneHelical%3B Name%3D1
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054642_46624203.05034.0TransmembraneHelical%3B Name%3D2
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054781_48034203.05034.0TransmembraneHelical%3B Name%3D3
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054805_48214203.05034.0TransmembraneHelical%3B Name%3D4
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054837_48574203.05034.0TransmembraneHelical%3B Name%3D5
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054921_49414203.05034.0TransmembraneHelical%3B Name%3D6
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064560_45804208.05039.0TransmembraneHelical%3B Name%3D1
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064642_46624208.05039.0TransmembraneHelical%3B Name%3D2
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064781_48034208.05039.0TransmembraneHelical%3B Name%3D3
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064805_48214208.05039.0TransmembraneHelical%3B Name%3D4
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064837_48574208.05039.0TransmembraneHelical%3B Name%3D5
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064921_49414208.05039.0TransmembraneHelical%3B Name%3D6
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054560_45804203.05034.0TransmembraneHelical%3B Name%3D1
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054642_46624203.05034.0TransmembraneHelical%3B Name%3D2
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054781_48034203.05034.0TransmembraneHelical%3B Name%3D3
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054805_48214203.05034.0TransmembraneHelical%3B Name%3D4
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054837_48574203.05034.0TransmembraneHelical%3B Name%3D5
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054921_49414203.05034.0TransmembraneHelical%3B Name%3D6

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneFBLchr19:40336931chr19:39055599ENST00000221801-198_773.3333333333333335322.0Compositional biasNote=DMA/Gly-rich
HgeneFBLchr19:40336931chr19:39055599ENST00000221801-19172_1733.3333333333333335322.0RegionS-adenosyl-L-methionine binding
HgeneFBLchr19:40336931chr19:39055599ENST00000221801-19191_1923.3333333333333335322.0RegionS-adenosyl-L-methionine binding
HgeneFBLchr19:40336931chr19:39055599ENST00000221801-19216_2173.3333333333333335322.0RegionS-adenosyl-L-methionine binding
HgeneFBLchr19:40336931chr19:39055599ENST00000221801-19236_2393.3333333333333335322.0RegionS-adenosyl-L-methionine binding
HgeneFBLchr19:40336931chr19:39055599ENST00000221801-19274_3063.3333333333333335322.0RegionHelical
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881051873_19244203.05034.0Compositional biasNote=Glu-rich (acidic)
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891061873_19244208.05039.0Compositional biasNote=Glu-rich (acidic)
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881051873_19244203.05034.0Compositional biasNote=Glu-rich (acidic)
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881051013_12084203.05034.0DomainB30.2/SPRY 2
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881051356_15704203.05034.0DomainB30.2/SPRY 3
TgeneRYR1chr19:40336931chr19:39055599ENST0000035548188105159_2044203.05034.0DomainMIR 2
TgeneRYR1chr19:40336931chr19:39055599ENST0000035548188105210_2644203.05034.0DomainMIR 3
TgeneRYR1chr19:40336931chr19:39055599ENST0000035548188105270_3274203.05034.0DomainMIR 4
TgeneRYR1chr19:40336931chr19:39055599ENST0000035548188105335_3924203.05034.0DomainMIR 5
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881054074_41024203.05034.0DomainEF-hand
TgeneRYR1chr19:40336931chr19:39055599ENST0000035548188105581_7974203.05034.0DomainB30.2/SPRY 1
TgeneRYR1chr19:40336931chr19:39055599ENST000003554818810597_1524203.05034.0DomainMIR 1
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891061013_12084208.05039.0DomainB30.2/SPRY 2
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891061356_15704208.05039.0DomainB30.2/SPRY 3
TgeneRYR1chr19:40336931chr19:39055599ENST0000035959689106159_2044208.05039.0DomainMIR 2
TgeneRYR1chr19:40336931chr19:39055599ENST0000035959689106210_2644208.05039.0DomainMIR 3
TgeneRYR1chr19:40336931chr19:39055599ENST0000035959689106270_3274208.05039.0DomainMIR 4
TgeneRYR1chr19:40336931chr19:39055599ENST0000035959689106335_3924208.05039.0DomainMIR 5
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891064074_41024208.05039.0DomainEF-hand
TgeneRYR1chr19:40336931chr19:39055599ENST0000035959689106581_7974208.05039.0DomainB30.2/SPRY 1
TgeneRYR1chr19:40336931chr19:39055599ENST000003595968910697_1524208.05039.0DomainMIR 1
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881051013_12084203.05034.0DomainB30.2/SPRY 2
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881051356_15704203.05034.0DomainB30.2/SPRY 3
TgeneRYR1chr19:40336931chr19:39055599ENST0000036098588105159_2044203.05034.0DomainMIR 2
TgeneRYR1chr19:40336931chr19:39055599ENST0000036098588105210_2644203.05034.0DomainMIR 3
TgeneRYR1chr19:40336931chr19:39055599ENST0000036098588105270_3274203.05034.0DomainMIR 4
TgeneRYR1chr19:40336931chr19:39055599ENST0000036098588105335_3924203.05034.0DomainMIR 5
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881054074_41024203.05034.0DomainEF-hand
TgeneRYR1chr19:40336931chr19:39055599ENST0000036098588105581_7974203.05034.0DomainB30.2/SPRY 1
TgeneRYR1chr19:40336931chr19:39055599ENST000003609858810597_1524203.05034.0DomainMIR 1
TgeneRYR1chr19:40336931chr19:39055599ENST0000035548188105841_29594203.05034.0RegionNote=6 X approximate repeats
TgeneRYR1chr19:40336931chr19:39055599ENST0000035959689106841_29594208.05039.0RegionNote=6 X approximate repeats
TgeneRYR1chr19:40336931chr19:39055599ENST0000036098588105841_29594203.05034.0RegionNote=6 X approximate repeats
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881051344_13594203.05034.0RepeatNote=3%3B truncated
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881051372_13874203.05034.0RepeatNote=4%3B truncated
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881052726_28454203.05034.0RepeatNote=5
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881052846_29594203.05034.0RepeatNote=6
TgeneRYR1chr19:40336931chr19:39055599ENST0000035548188105841_9544203.05034.0RepeatNote=1
TgeneRYR1chr19:40336931chr19:39055599ENST0000035548188105955_10684203.05034.0RepeatNote=2
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891061344_13594208.05039.0RepeatNote=3%3B truncated
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891061372_13874208.05039.0RepeatNote=4%3B truncated
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891062726_28454208.05039.0RepeatNote=5
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891062846_29594208.05039.0RepeatNote=6
TgeneRYR1chr19:40336931chr19:39055599ENST0000035959689106841_9544208.05039.0RepeatNote=1
TgeneRYR1chr19:40336931chr19:39055599ENST0000035959689106955_10684208.05039.0RepeatNote=2
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881051344_13594203.05034.0RepeatNote=3%3B truncated
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881051372_13874203.05034.0RepeatNote=4%3B truncated
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881052726_28454203.05034.0RepeatNote=5
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881052846_29594203.05034.0RepeatNote=6
TgeneRYR1chr19:40336931chr19:39055599ENST0000036098588105841_9544203.05034.0RepeatNote=1
TgeneRYR1chr19:40336931chr19:39055599ENST0000036098588105955_10684203.05034.0RepeatNote=2
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881051_45594203.05034.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891061_45594208.05039.0Topological domainCytoplasmic
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881051_45594203.05034.0Topological domainCytoplasmic


Top

Fusion Gene Sequence for FBL-RYR1


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>In-frame_ENST00000221801_ENST00000355481_TCGA-ER-A19T-01A_FBL_chr19_40336931_-_RYR1_chr19_39055599_length(transcript)=2761nt_BP=124nt
GCGTCACGCAGCGCACGTCGCCGCGCGCCTGCGCTCTTTTCCACGTGCGAAAGCCCCGGACTCGTGGAGTTGTGAACGCCGCGGACTCCG
GAGCCGCACAAACCAGGGCTCGCCATGAAGCCAGGTGAAGGAGTCCAAGCGCCAGTTCATCTTCGACGTGGTGAACGAGGGCGGCGAGGC
TGAGAAGATGGAGCTCTTCGTGAGTTTCTGCGAGGACACCATCTTCGAGATGCAGATCGCCGCGCAGATCTCGGAGCCCGAGGGCGAGCC
GGAGACCGACGAGGACGAGGGCGCGGGCGCGGCGGAGGCGGGCGCGGAAGGCGCGGAGGAGGGCGCGGCGGGGCTCGAGGGCACGGCGGC
CACGGCGGCGGCGGGGGCGACGGCGCGGGTTGTGGCGGCCGCAGGCCGGGCCCTGCGAGGCCTCAGCTACCGCAGCCTGCGGCGGCGCGT
GCGGCGGCTGCGGCGGCTTACGGCCCGCGAGGCGGCCACCGCAGTGGCGGCGCTGCTCTGGGCAGCAGTGACGCGCGCTGGGGCCGCTGG
CGCGGGGGCGGCGGCGGGCGCGCTGGGCCTGCTCTGGGGCTCGCTGTTCGGCGGCGGCCTGGTGGAGGGCGCCAAGAAGGTGACGGTGAC
CGAGCTCCTGGCAGGCATGCCCGACCCCACCAGCGACGAGGTGCACGGCGAGCAGCCGGCCGGGCCGGGCGGAGACGCAGACGGCGAGGG
TGCCAGCGAGGGCGCTGGAGACGCCGCGGAGGGCGCTGGAGACGAGGAGGAGGCGGTGCACGAGGCCGGGCCGGGCGGTGCCGACGGGGC
GGTGGCCGTGACCGATGGGGGCCCCTTCCGGCCCGAAGGGGCTGGCGGTCTCGGGGACATGGGGGACACGACGCCTGCGGAACCGCCCAC
ACCCGAGGGCTCTCCCATCCTCAAGAGGAAATTGGGGGTGGATGGAGTGGAGGAGGAGCTCCCGCCAGAGCCAGAGCCCGAGCCGGAACC
AGAGCTGGAGCCGGAGAAAGCCGATGCCGAGAATGGGGAGAAGGAAGAAGTTCCCGAGCCCACACCAGAGCCCCCCAAGAAGCAAGCACC
TCCCTCACCCCCTCCAAAGAAGGAGGAAGCTGGAGGCGAATTCTGGGGAGAACTGGAGGTGCAGAGGGTGAAGTTCCTGAACTACCTGTC
CCGGAACTTTTACACCCTGCGGTTCCTTGCCCTCTTCTTGGCATTTGCCATCAACTTCATCTTGCTGTTTTATAAGGTCTCAGACTCTCC
ACCAGGGGAGGACGACATGGAAGGCTCAGCTGCTGGGGATGTGTCAGGTGCAGGCTCTGGTGGCAGCTCTGGCTGGGGCTTGGGGGCCGG
AGAGGAGGCAGAGGGCGATGAGGATGAGAACATGGTGTACTACTTCCTGGAGGAAAGCACAGGCTACATGGAACCCGCCCTGCGGTGTCT
GAGCCTCCTGCATACACTGGTGGCCTTTCTCTGCATCATTGGCTATAATTGTCTCAAGGTGCCCCTGGTAATCTTTAAGCGGGAGAAGGA
GCTGGCCCGGAAGCTGGAGTTTGATGGCCTGTACATCACGGAGCAGCCTGAGGACGATGACGTGAAGGGGCAGTGGGACCGACTGGTGCT
CAACACGCCGTCTTTCCCTAGCAACTACTGGGACAAGTTTGTCAAGCGCAAGGTCCTGGACAAACATGGGGACATCTACGGGCGGGAGCG
GATTGCTGAGCTACTGGGCATGGACCTGGCCACACTAGAGATCACAGCCCACAATGAGCGCAAGCCCAACCCGCCGCCAGGGCTGCTGAC
CTGGCTCATGTCCATCGATGTCAAGTACCAGATCTGGAAGTTCGGGGTCATCTTCACAGACAACTCCTTCCTGTACCTGGGCTGGTATAT
GGTGATGTCCCTCTTGGGACACTACAACAACTTCTTCTTTGCTGCCCATCTCCTGGACATCGCCATGGGGGTCAAGACGCTGCGCACCAT
CCTGTCCTCTGTCACCCACAATGGGAAACAGCTGGTGATGACCGTGGGCCTTCTGGCGGTGGTCGTCTACCTGTACACCGTGGTGGCCTT
CAACTTCTTCCGCAAGTTCTACAACAAGAGCGAGGATGAGGATGAACCTGACATGAAGTGTGATGACATGATGACGTGTTACCTGTTTCA
CATGTACGTGGGTGTCCGGGCTGGCGGAGGCATTGGGGACGAGATCGAGGACCCCGCGGGTGACGAATACGAGCTCTACAGGGTGGTCTT
CGACATCACCTTCTTCTTCTTCGTCATCGTCATCCTGTTGGCCATCATCCAGGGTCTGATCATCGACGCTTTTGGTGAGCTCCGAGACCA
ACAAGAGCAAGTGAAGGAGGATATGGAGACCAAGTGCTTCATCTGTGGAATCGGCAGTGACTACTTTGATACGACACCGCATGGCTTCGA
GACTCACACGCTGGAGGAGCACAACCTGGCCAATTACATGTTTTTCCTGATGTATTTGATAAACAAGGATGAGACAGAACACACGGGTCA
GGAGTCTTATGTCTGGAAGATGTACCAAGAGAGATGTTGGGATTTCTTCCCAGCTGGTGATTGTTTCCGTAAGCAGTATGAGGACCAGCT
TAGCTGACACACCCCCAGCTGGCCCTCCACCCCCACCTCAAGTGCCTTATTCTCACAGCAAGCCCCTTAGTCCCCAAGCCCCTCCCCCTA

>In-frame_ENST00000221801_ENST00000355481_TCGA-ER-A19T-01A_FBL_chr19_40336931_-_RYR1_chr19_39055599_length(amino acids)=809AA_start in transcript=187_stop in transcript=2616
MELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRR
LRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGAS
EGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPEL
EPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPG
EDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELA
RKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWL
MSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNF
FRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQE

--------------------------------------------------------------
>In-frame_ENST00000221801_ENST00000360985_TCGA-ER-A19T-01A_FBL_chr19_40336931_-_RYR1_chr19_39055599_length(transcript)=2761nt_BP=124nt
GCGTCACGCAGCGCACGTCGCCGCGCGCCTGCGCTCTTTTCCACGTGCGAAAGCCCCGGACTCGTGGAGTTGTGAACGCCGCGGACTCCG
GAGCCGCACAAACCAGGGCTCGCCATGAAGCCAGGTGAAGGAGTCCAAGCGCCAGTTCATCTTCGACGTGGTGAACGAGGGCGGCGAGGC
TGAGAAGATGGAGCTCTTCGTGAGTTTCTGCGAGGACACCATCTTCGAGATGCAGATCGCCGCGCAGATCTCGGAGCCCGAGGGCGAGCC
GGAGACCGACGAGGACGAGGGCGCGGGCGCGGCGGAGGCGGGCGCGGAAGGCGCGGAGGAGGGCGCGGCGGGGCTCGAGGGCACGGCGGC
CACGGCGGCGGCGGGGGCGACGGCGCGGGTTGTGGCGGCCGCAGGCCGGGCCCTGCGAGGCCTCAGCTACCGCAGCCTGCGGCGGCGCGT
GCGGCGGCTGCGGCGGCTTACGGCCCGCGAGGCGGCCACCGCAGTGGCGGCGCTGCTCTGGGCAGCAGTGACGCGCGCTGGGGCCGCTGG
CGCGGGGGCGGCGGCGGGCGCGCTGGGCCTGCTCTGGGGCTCGCTGTTCGGCGGCGGCCTGGTGGAGGGCGCCAAGAAGGTGACGGTGAC
CGAGCTCCTGGCAGGCATGCCCGACCCCACCAGCGACGAGGTGCACGGCGAGCAGCCGGCCGGGCCGGGCGGAGACGCAGACGGCGAGGG
TGCCAGCGAGGGCGCTGGAGACGCCGCGGAGGGCGCTGGAGACGAGGAGGAGGCGGTGCACGAGGCCGGGCCGGGCGGTGCCGACGGGGC
GGTGGCCGTGACCGATGGGGGCCCCTTCCGGCCCGAAGGGGCTGGCGGTCTCGGGGACATGGGGGACACGACGCCTGCGGAACCGCCCAC
ACCCGAGGGCTCTCCCATCCTCAAGAGGAAATTGGGGGTGGATGGAGTGGAGGAGGAGCTCCCGCCAGAGCCAGAGCCCGAGCCGGAACC
AGAGCTGGAGCCGGAGAAAGCCGATGCCGAGAATGGGGAGAAGGAAGAAGTTCCCGAGCCCACACCAGAGCCCCCCAAGAAGCAAGCACC
TCCCTCACCCCCTCCAAAGAAGGAGGAAGCTGGAGGCGAATTCTGGGGAGAACTGGAGGTGCAGAGGGTGAAGTTCCTGAACTACCTGTC
CCGGAACTTTTACACCCTGCGGTTCCTTGCCCTCTTCTTGGCATTTGCCATCAACTTCATCTTGCTGTTTTATAAGGTCTCAGACTCTCC
ACCAGGGGAGGACGACATGGAAGGCTCAGCTGCTGGGGATGTGTCAGGTGCAGGCTCTGGTGGCAGCTCTGGCTGGGGCTTGGGGGCCGG
AGAGGAGGCAGAGGGCGATGAGGATGAGAACATGGTGTACTACTTCCTGGAGGAAAGCACAGGCTACATGGAACCCGCCCTGCGGTGTCT
GAGCCTCCTGCATACACTGGTGGCCTTTCTCTGCATCATTGGCTATAATTGTCTCAAGGTGCCCCTGGTAATCTTTAAGCGGGAGAAGGA
GCTGGCCCGGAAGCTGGAGTTTGATGGCCTGTACATCACGGAGCAGCCTGAGGACGATGACGTGAAGGGGCAGTGGGACCGACTGGTGCT
CAACACGCCGTCTTTCCCTAGCAACTACTGGGACAAGTTTGTCAAGCGCAAGGTCCTGGACAAACATGGGGACATCTACGGGCGGGAGCG
GATTGCTGAGCTACTGGGCATGGACCTGGCCACACTAGAGATCACAGCCCACAATGAGCGCAAGCCCAACCCGCCGCCAGGGCTGCTGAC
CTGGCTCATGTCCATCGATGTCAAGTACCAGATCTGGAAGTTCGGGGTCATCTTCACAGACAACTCCTTCCTGTACCTGGGCTGGTATAT
GGTGATGTCCCTCTTGGGACACTACAACAACTTCTTCTTTGCTGCCCATCTCCTGGACATCGCCATGGGGGTCAAGACGCTGCGCACCAT
CCTGTCCTCTGTCACCCACAATGGGAAACAGCTGGTGATGACCGTGGGCCTTCTGGCGGTGGTCGTCTACCTGTACACCGTGGTGGCCTT
CAACTTCTTCCGCAAGTTCTACAACAAGAGCGAGGATGAGGATGAACCTGACATGAAGTGTGATGACATGATGACGTGTTACCTGTTTCA
CATGTACGTGGGTGTCCGGGCTGGCGGAGGCATTGGGGACGAGATCGAGGACCCCGCGGGTGACGAATACGAGCTCTACAGGGTGGTCTT
CGACATCACCTTCTTCTTCTTCGTCATCGTCATCCTGTTGGCCATCATCCAGGGTCTGATCATCGACGCTTTTGGTGAGCTCCGAGACCA
ACAAGAGCAAGTGAAGGAGGATATGGAGACCAAGTGCTTCATCTGTGGAATCGGCAGTGACTACTTTGATACGACACCGCATGGCTTCGA
GACTCACACGCTGGAGGAGCACAACCTGGCCAATTACATGTTTTTCCTGATGTATTTGATAAACAAGGATGAGACAGAACACACGGGTCA
GGAGTCTTATGTCTGGAAGATGTACCAAGAGAGATGTTGGGATTTCTTCCCAGCTGGTGATTGTTTCCGTAAGCAGTATGAGGACCAGCT
TAGCTGACACACCCCCAGCTGGCCCTCCACCCCCACCTCAAGTGCCTTATTCTCACAGCAAGCCCCTTAGTCCCCAAGCCCCTCCCCCTA

>In-frame_ENST00000221801_ENST00000360985_TCGA-ER-A19T-01A_FBL_chr19_40336931_-_RYR1_chr19_39055599_length(amino acids)=809AA_start in transcript=187_stop in transcript=2616
MELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRR
LRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGAS
EGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPEL
EPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPG
EDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELA
RKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWL
MSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNF
FRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQE

--------------------------------------------------------------
>In-frame_ENST00000221801_ENST00000359596_TCGA-ER-A19T-01A_FBL_chr19_40336931_-_RYR1_chr19_39055599_length(transcript)=2617nt_BP=124nt
GCGTCACGCAGCGCACGTCGCCGCGCGCCTGCGCTCTTTTCCACGTGCGAAAGCCCCGGACTCGTGGAGTTGTGAACGCCGCGGACTCCG
GAGCCGCACAAACCAGGGCTCGCCATGAAGCCAGGTGAAGGAGTCCAAGCGCCAGTTCATCTTCGACGTGGTGAACGAGGGCGGCGAGGC
TGAGAAGATGGAGCTCTTCGTGAGTTTCTGCGAGGACACCATCTTCGAGATGCAGATCGCCGCGCAGATCTCGGAGCCCGAGGGCGAGCC
GGAGACCGACGAGGACGAGGGCGCGGGCGCGGCGGAGGCGGGCGCGGAAGGCGCGGAGGAGGGCGCGGCGGGGCTCGAGGGCACGGCGGC
CACGGCGGCGGCGGGGGCGACGGCGCGGGTTGTGGCGGCCGCAGGCCGGGCCCTGCGAGGCCTCAGCTACCGCAGCCTGCGGCGGCGCGT
GCGGCGGCTGCGGCGGCTTACGGCCCGCGAGGCGGCCACCGCAGTGGCGGCGCTGCTCTGGGCAGCAGTGACGCGCGCTGGGGCCGCTGG
CGCGGGGGCGGCGGCGGGCGCGCTGGGCCTGCTCTGGGGCTCGCTGTTCGGCGGCGGCCTGGTGGAGGGCGCCAAGAAGGTGACGGTGAC
CGAGCTCCTGGCAGGCATGCCCGACCCCACCAGCGACGAGGTGCACGGCGAGCAGCCGGCCGGGCCGGGCGGAGACGCAGACGGCGAGGG
TGCCAGCGAGGGCGCTGGAGACGCCGCGGAGGGCGCTGGAGACGAGGAGGAGGCGGTGCACGAGGCCGGGCCGGGCGGTGCCGACGGGGC
GGTGGCCGTGACCGATGGGGGCCCCTTCCGGCCCGAAGGGGCTGGCGGTCTCGGGGACATGGGGGACACGACGCCTGCGGAACCGCCCAC
ACCCGAGGGCTCTCCCATCCTCAAGAGGAAATTGGGGGTGGATGGAGTGGAGGAGGAGCTCCCGCCAGAGCCAGAGCCCGAGCCGGAACC
AGAGCTGGAGCCGGAGAAAGCCGATGCCGAGAATGGGGAGAAGGAAGAAGTTCCCGAGCCCACACCAGAGCCCCCCAAGAAGCAAGCACC
TCCCTCACCCCCTCCAAAGAAGGAGGAAGCTGGAGGCGAATTCTGGGGAGAACTGGAGGTGCAGAGGGTGAAGTTCCTGAACTACCTGTC
CCGGAACTTTTACACCCTGCGGTTCCTTGCCCTCTTCTTGGCATTTGCCATCAACTTCATCTTGCTGTTTTATAAGGTCTCAGACTCTCC
ACCAGGGGAGGACGACATGGAAGGCTCAGCTGCTGGGGATGTGTCAGGTGCAGGCTCTGGTGGCAGCTCTGGCTGGGGCTTGGGGGCCGG
AGAGGAGGCAGAGGGCGATGAGGATGAGAACATGGTGTACTACTTCCTGGAGGAAAGCACAGGCTACATGGAACCCGCCCTGCGGTGTCT
GAGCCTCCTGCATACACTGGTGGCCTTTCTCTGCATCATTGGCTATAATTGTCTCAAGGTGCCCCTGGTAATCTTTAAGCGGGAGAAGGA
GCTGGCCCGGAAGCTGGAGTTTGATGGCCTGTACATCACGGAGCAGCCTGAGGACGATGACGTGAAGGGGCAGTGGGACCGACTGGTGCT
CAACACGCCGTCTTTCCCTAGCAACTACTGGGACAAGTTTGTCAAGCGCAAGGTCCTGGACAAACATGGGGACATCTACGGGCGGGAGCG
GATTGCTGAGCTACTGGGCATGGACCTGGCCACACTAGAGATCACAGCCCACAATGAGCGCAAGCCCAACCCGCCGCCAGGGCTGCTGAC
CTGGCTCATGTCCATCGATGTCAAGTACCAGATCTGGAAGTTCGGGGTCATCTTCACAGACAACTCCTTCCTGTACCTGGGCTGGTATAT
GGTGATGTCCCTCTTGGGACACTACAACAACTTCTTCTTTGCTGCCCATCTCCTGGACATCGCCATGGGGGTCAAGACGCTGCGCACCAT
CCTGTCCTCTGTCACCCACAATGGGAAACAGCTGGTGATGACCGTGGGCCTTCTGGCGGTGGTCGTCTACCTGTACACCGTGGTGGCCTT
CAACTTCTTCCGCAAGTTCTACAACAAGAGCGAGGATGAGGATGAACCTGACATGAAGTGTGATGACATGATGACGTGTTACCTGTTTCA
CATGTACGTGGGTGTCCGGGCTGGCGGAGGCATTGGGGACGAGATCGAGGACCCCGCGGGTGACGAATACGAGCTCTACAGGGTGGTCTT
CGACATCACCTTCTTCTTCTTCGTCATCGTCATCCTGTTGGCCATCATCCAGGGTCTGATCATCGACGCTTTTGGTGAGCTCCGAGACCA
ACAAGAGCAAGTGAAGGAGGATATGGAGACCAAGTGCTTCATCTGTGGAATCGGCAGTGACTACTTTGATACGACACCGCATGGCTTCGA
GACTCACACGCTGGAGGAGCACAACCTGGCCAATTACATGTTTTTCCTGATGTATTTGATAAACAAGGATGAGACAGAACACACGGGTCA
GGAGTCTTATGTCTGGAAGATGTACCAAGAGAGATGTTGGGATTTCTTCCCAGCTGGTGATTGTTTCCGTAAGCAGTATGAGGACCAGCT

>In-frame_ENST00000221801_ENST00000359596_TCGA-ER-A19T-01A_FBL_chr19_40336931_-_RYR1_chr19_39055599_length(amino acids)=810AA_start in transcript=187_stop in transcript=2616
MELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAAGLEGTAATAAAGATARVVAAAGRALRGLSYRSLRRRVRR
LRRLTAREAATAVAALLWAAVTRAGAAGAGAAAGALGLLWGSLFGGGLVEGAKKVTVTELLAGMPDPTSDEVHGEQPAGPGGDADGEGAS
EGAGDAAEGAGDEEEAVHEAGPGGADGAVAVTDGGPFRPEGAGGLGDMGDTTPAEPPTPEGSPILKRKLGVDGVEEELPPEPEPEPEPEL
EPEKADAENGEKEEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWGELEVQRVKFLNYLSRNFYTLRFLALFLAFAINFILLFYKVSDSPPG
EDDMEGSAAGDVSGAGSGGSSGWGLGAGEEAEGDEDENMVYYFLEESTGYMEPALRCLSLLHTLVAFLCIIGYNCLKVPLVIFKREKELA
RKLEFDGLYITEQPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEITAHNERKPNPPPGLLTWL
MSIDVKYQIWKFGVIFTDNSFLYLGWYMVMSLLGHYNNFFFAAHLLDIAMGVKTLRTILSSVTHNGKQLVMTVGLLAVVVYLYTVVAFNF
FRKFYNKSEDEDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDEYELYRVVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQE
QVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYMFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLSX

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for FBL-RYR1


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with
TgeneRYR1chr19:40336931chr19:39055599ENST00000355481881053614_36434203.05034.0CALM
TgeneRYR1chr19:40336931chr19:39055599ENST00000359596891063614_36434208.05039.0CALM
TgeneRYR1chr19:40336931chr19:39055599ENST00000360985881053614_36434203.05034.0CALM
TgeneRYR1chr19:40336931chr19:39055599ENST0000035548188105669_6804203.05034.0FKBP1A
TgeneRYR1chr19:40336931chr19:39055599ENST0000035959689106669_6804208.05039.0FKBP1A
TgeneRYR1chr19:40336931chr19:39055599ENST0000036098588105669_6804203.05034.0FKBP1A


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for FBL-RYR1


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status

Top

Related Diseases for FBL-RYR1


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneFBLC0004364Autoimmune Diseases3CTD_human
HgeneFBLC0006142Malignant neoplasm of breast1CTD_human
HgeneFBLC0152013Adenocarcinoma of lung (disorder)1CTD_human
HgeneFBLC0678222Breast Carcinoma1CTD_human
HgeneFBLC1257931Mammary Neoplasms, Human1CTD_human
HgeneFBLC1458155Mammary Neoplasms1CTD_human
HgeneFBLC4704874Mammary Carcinoma, Human1CTD_human
TgeneRYR1C2930980Malignant hyperthermia susceptibility type 146CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneRYR1C0751951Central Core Myopathy (disorder)32CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneRYR1C0024591Malignant hyperpyrexia due to anesthesia10CTD_human;GENOMICS_ENGLAND
TgeneRYR1C1850674MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA (disorder)5CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
TgeneRYR1C1840365King Denborough syndrome2ORPHANET
TgeneRYR1C3645536Autosomal Recessive Centronuclear Myopathy2CTD_human;ORPHANET
TgeneRYR1C0007134Renal Cell Carcinoma1CTD_human
TgeneRYR1C0008928Cleidocranial Dysplasia1GENOMICS_ENGLAND
TgeneRYR1C0175709Centronuclear myopathy1CTD_human
TgeneRYR1C0265261Multiple pterygium syndrome1GENOMICS_ENGLAND
TgeneRYR1C0270960Congenital myopathy (disorder)1GENOMICS_ENGLAND
TgeneRYR1C0279702Conventional (Clear Cell) Renal Cell Carcinoma1CTD_human
TgeneRYR1C0410203X-linked centronuclear myopathy1CTD_human
TgeneRYR1C0410204Myopathy, Centronuclear, Autosomal Recessive1ORPHANET
TgeneRYR1C0410207Tubular Aggregate Myopathy1CTD_human
TgeneRYR1C0546264Congenital Fiber Type Disproportion1CTD_human
TgeneRYR1C0752282Congenital Structural Myopathy1CTD_human
TgeneRYR1C1266042Chromophobe Renal Cell Carcinoma1CTD_human
TgeneRYR1C1266043Sarcomatoid Renal Cell Carcinoma1CTD_human
TgeneRYR1C1266044Collecting Duct Carcinoma of the Kidney1CTD_human
TgeneRYR1C1306837Papillary Renal Cell Carcinoma1CTD_human
TgeneRYR1C1834558Myopathy, Centronuclear, Autosomal Dominant1CTD_human;ORPHANET
TgeneRYR1C1854678MULTIPLE PTERYGIUM SYNDROME, LETHAL TYPE1ORPHANET
TgeneRYR1C1861753Multiminicore Disease, Moderate, with Hand Involvement1ORPHANET
TgeneRYR1C3661489Autosomal Dominant Myotubular Myopathy1CTD_human
TgeneRYR1C4551952Myopathy, Centronuclear, 11CTD_human
TgeneRYR1C4706390Congenital myopathy with myasthenic-like onset1ORPHANET
TgeneRYR1C4749502Benign Samaritan congenital myopathy1ORPHANET